Senior Director, Medical Affairs
Invivyd, Inc.
Waltham, Massachusetts, United States
Disclosure(s): Invivyd, Inc.: Employee, Stocks/Bonds (Public Company)
91 - Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating Pemivibart
Thursday, October 17, 2024
11:18 AM – 11:30 AM US PT